Navigation Links
Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at

Dallas, Texas (PRWEB) March 30, 2013

This report provides an overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response. Analysis of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017. Also evaluates technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages. The reports discusses CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others. The report provides patent analysis. And comprehensive company profiles of major players.

Report Scope
Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, indicate what treatment options may be most effective in an individual patient’s case and predict treatment response. They play a role both in new drug R&D and in predicting the outcome of treatment in the medical setting. They are important tools for understanding disease mechanism, developing more effective treatments and improving the quality of patient care.

The report examines the role of CNS biomarkers in early discovery, in drug development and for future diagnostics. The global CNS biomarker market ( is discussed, and forecasts are made for this segment of the industry for the five-year period from 2012 to 2017. The technological segments of the market (genomics, proteomics and molecular diagnostics) are discussed by application, technology and geographic region. Individual disease segments are also discussed and describe gaps in treatment and limitations of current methods of diagnosis. The process of developing biomarkers from discovery to commercialization is described along with the forces in the industry that play an integral role, such as payers, providers and suppliers. Growth drivers and inhibitors that can affect CNS biomarker development and adoption are also discussed.

Study Goals and Objectives

  •     Assess the various technologies used for CNS biomarker discovery and future diagnostics.
  •     Understand the process of CNS biomarker development from discovery to commercialization and the path towards adoption.
  •     Examine the regulatory landscape and government’s role.
  •     Examine the future advances that need to be made in the diagnosis and treatment of various CNS disorders.
  •     Determine current and future CNS biomarker markets.

Buy a copy of report @

Scope of Report
Current and projected product forecasts during the forecast period of 2012 to 2017 are discussed. New product launches will be discussed. Revenue figures for 2011 are actual figures. Revenue figures for 2012 are actual figures except where actual results have not been reported, due to the timing of the release of the report.

The report includes an analysis of leading and emerging CNS biomarkers and related drugs for each CNS disorder. Profiles of producers of leading products and their specific products are provided. The report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving CNS biomarker diagnostics and treatment with associated drugs.

Market figures are based on revenues at the manufacturers’ level and are projected at a 2012-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2012 through 2017. The study is arranged to offer an overview of existing biomarker technology, drug markets for CNS diseases, drug and disease mechanism of action and companies, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information is reviewed for various candidate biomarkers. The status of approval by the FDA and regulatory agencies in other countries of biomarker diagnostics in each segment is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

Explore more reports on Biotechnology Market @

About Us is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. A molecule central to diabetes is uncovered
3. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
4. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
5. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
6. ‘Timely’ new undergrad program in photonics at University of Central Florida applauded by SPIE
7. Site Quality Management to Optimize Risk-Based and Centralized Monitoring, New Life Science Webinar Hosted by Xtalks
8. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
9. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
10. Dicom Systems and Announce Partnership and Introduce Beta Version of, New System by
11. Ellmans Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors
Post Your Comments:
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... York , November 24, 2015 ... a recent market research report released by Transparency Market ... to expand at a CAGR of 17.5% during the ... Prenatal Testing Market - Global Industry Analysis, Size, Volume, ... the global non-invasive prenatal testing market to reach a ...
Breaking Biology Technology:
(Date:10/26/2015)... Calif. , Oct. 26, 2015  Delta ID ... biometric authentication to mobile and PC devices, announced its ... smartphone, the arrows NX F-02H launched by NTT DOCOMO, ... NX F-02H is the second smartphone to include iris ... technology in ARROWS NX F-04G in May 2015, world,s ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a ... its first quarter ended September 30, 2015. ... of fiscal 2016 grew 66 percent over the comparable quarter last ... fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... for the first quarter of fiscal 2016 grew 39 percent over ...
Breaking Biology News(10 mins):